諾誠健華宣佈宜諾凱(奧布替尼)在新加坡獲批用於治療套細胞淋巴瘤
格隆匯11月22日丨生物醫藥高科技公司諾誠健華(9969.HK)今天宣佈,宜諾凱(奧布替尼)已獲得新加坡衞生科學局(HSA)的批准,用於治療復發/難治性套細胞淋巴瘤(R/R MCL)成人患者。諾誠健華聯合創始人、董事長兼CEO崔霽松博士説:“奧布替尼在新加坡的上市獲批標誌着諾誠健華商業化走向國際。奧布替尼作為高選擇性BTK抑制劑,在治療復發/難治性套細胞淋巴瘤中顯示了良好的有效性和安全性。此次在新加坡獲批,奧布替尼將為當地套細胞淋巴瘤患者帶來創新療法的選擇。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.